product summary
Loading...
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
antibody
product name :
p53 Monoclonal Antibody (DO-1)
catalog :
AHO0152
quantity :
500 µL
price :
US 450.00
clonality :
monoclonal
host :
mouse
conjugate :
nonconjugated
clone name :
DO-1
reactivity :
human, mouse, rat, rhesus macaque
application :
western blot, immunohistochemistry, immunocytochemistry, immunoprecipitation, immunohistochemistry - paraffin section, immunohistochemistry - frozen section, western blot knockout validation
more info or order :
Invitrogen product webpage
citations: 38
Published Application/Species/Sample/DilutionReference
  • western blot knockout validation; mouse; fig 7
  • western blot knockout validation; human; fig 7
Itahana K, Zhang Y. Mitochondrial p32 is a critical mediator of ARF-induced apoptosis. Cancer Cell. 2008;13:542-53 pubmed publisher
  • western blot; human; loading ...; fig 4a
Leslie P, Franklin D, Liu Y, Zhang Y. p53 Regulates the Expression of LRP1 and Apoptosis through a Stress Intensity-Dependent MicroRNA Feedback Loop. Cell Rep. 2018;24:1484-1495 pubmed publisher
  • western blot; human; loading ...; fig 1c
Bernal A, Moltó Abad M, Dominguez D, Tusell L. Acute telomere deprotection prevents ongoing BFB cycles and rampant instability in p16INK4a-deficient epithelial cells. Oncotarget. 2018;9:27151-27170 pubmed publisher
  • immunohistochemistry - frozen section; human; 1:100; loading ...; fig 1a
Pommier A, Anaparthy N, Memos N, Kelley Z, Gouronnec A, Yan R, et al. Unresolved endoplasmic reticulum stress engenders immune-resistant, latent pancreatic cancer metastases. Science. 2018;360: pubmed publisher
  • immunocytochemistry; rat; 1:100; loading ...; fig 1b
Bryukhovetskiy I, Lyakhova I, Mischenko P, Milkina E, Zaitsev S, Khotimchenko Y, et al. Alkaloids of fascaplysin are effective conventional chemotherapeutic drugs, inhibiting the proliferation of C6 glioma cells and causing their death in vitro. Oncol Lett. 2017;13:738-746 pubmed publisher
  • immunohistochemistry - paraffin section; human; loading ...; fig 2
Walline H, Carey T, Goudsmit C, Bellile E, D Souza G, Peterson L, et al. High-Risk HPV, Biomarkers, and Outcome in Matched Cohorts of Head and Neck Cancer Patients Positive and Negative for HIV. Mol Cancer Res. 2017;15:179-188 pubmed publisher
  • immunocytochemistry; rat; 1:100; loading ...
Bryukhovetskiy I, Dyuizen I, Shevchenko V, Bryukhovetskiy A, Mischenko P, Milkina E, et al. Hematopoietic stem cells as a tool for the treatment of glioblastoma multiforme. Mol Med Rep. 2016;14:4511-4520 pubmed publisher
  • immunocytochemistry; rat; 1:100; fig 1
Bryukhovetskiy I, Manzhulo I, Mischenko P, Milkina E, Dyuizen I, Bryukhovetskiy A, et al. Cancer stem cells and microglia in the processes of glioblastoma multiforme invasive growth. Oncol Lett. 2016;12:1721-1728 pubmed
  • western blot; human; loading ...; fig 2a
Liu X, Wang S, Guo X, Wei F, Yin J, Zang Y, et al. Exogenous p53 and ASPP2 expression enhances rAdV-TK/ GCV-induced death in hepatocellular carcinoma cells lacking functional p53. Oncotarget. 2016;7:18896-905 pubmed publisher
  • western blot; human; loading ...; fig s2a
Gruosso T, Garnier C, Abélanet S, Kieffer Y, Lemesre V, Bellanger D, et al. MAP3K8/TPL-2/COT is a potential predictive marker for MEK inhibitor treatment in high-grade serous ovarian carcinomas. Nat Commun. 2015;6:8583 pubmed publisher
  • immunohistochemistry; human; 1:200; fig 3
Catenacci D, Chapman C, Xu P, Koons A, Konda V, Siddiqui U, et al. Acquisition of Portal Venous Circulating Tumor Cells From Patients With Pancreaticobiliary Cancers by Endoscopic Ultrasound. Gastroenterology. 2015;149:1794-1803.e4 pubmed publisher
  • immunoprecipitation; human
  • western blot; human
Leslie P, Ke H, Zhang Y. The MDM2 RING domain and central acidic domain play distinct roles in MDM2 protein homodimerization and MDM2-MDMX protein heterodimerization. J Biol Chem. 2015;290:12941-50 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100
Beck A, Brooks A, Zeiss C. Invasive ductular carcinoma in 2 rhesus macaques (Macaca mulatta). Comp Med. 2014;64:314-22 pubmed
  • western blot; human; 1:1000
Senkiv Y, Riabtseva A, Heffeter P, Boiko N, Kowol C, Jungwith U, et al. Enhanced anticancer activity and circumvention of resistance mechanisms by novel polymeric/ phospholipidic nanocarriers of doxorubicin. J Biomed Nanotechnol. 2014;10:1369-81 pubmed
  • western blot; human
Wilking M, SINGH C, Nihal M, Zhong W, Ahmad N. SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys. 2014;563:94-100 pubmed publisher
  • immunohistochemistry - paraffin section; human; 1:100
Bradford C, Kumar B, Bellile E, Lee J, Taylor J, D SILVA N, et al. Biomarkers in advanced larynx cancer. Laryngoscope. 2014;124:179-87 pubmed publisher
  • immunohistochemistry - paraffin section; human
Yang B, Ma C, Chen Z, Yi W, McNutt M, Wang Y, et al. Correlation of immunoglobulin G expression and histological subtype and stage in breast cancer. PLoS ONE. 2013;8:e58706 pubmed publisher
  • western blot; human; fig 1
Mesplede T, Gagnon D, Bergeron Labrecque F, Azar I, Sénéchal H, Coutlee F, et al. p53 degradation activity, expression, and subcellular localization of E6 proteins from 29 human papillomavirus genotypes. J Virol. 2012;86:94-107 pubmed publisher
Mohibi S, Chen X, Zhang J. ZFP14 Regulates Cancer Cell Growth and Migration by Modulating p53 Protein Stability as Part of the MDM2 E3 Ubiquitin Ligase Complex. Cancers (Basel). 2022;14: pubmed publisher
Shayan S, Arashkia A, Bahramali G, Abdoli A, Nosrati M, Azadmanesh K. Cell type-specific response of colon cancer tumor cell lines to oncolytic HSV-1 virotherapy in hypoxia. Cancer Cell Int. 2022;22:164 pubmed publisher
Manzella G, Schreck L, Breunis W, Molenaar J, Merks H, Barr F, et al. Phenotypic profiling with a living biobank of primary rhabdomyosarcoma unravels disease heterogeneity and AKT sensitivity. Nat Commun. 2020;11:4629 pubmed publisher
Mair B, Tomic J, Masud S, Tonge P, Weiss A, Usaj M, et al. Essential Gene Profiles for Human Pluripotent Stem Cells Identify Uncharacterized Genes and Substrate Dependencies. Cell Rep. 2019;27:599-615.e12 pubmed publisher
Liao P, Zeng S, Zhou X, Chen T, Zhou F, Cao B, et al. Mutant p53 Gains Its Function via c-Myc Activation upon CDK4 Phosphorylation at Serine 249 and Consequent PIN1 Binding. Mol Cell. 2017;68:1134-1146.e6 pubmed publisher
Chen G, Zhou G, Aras S, He Z, Lucas S, Podgorski I, et al. Loss of ABHD5 promotes the aggressiveness of prostate cancer cells. Sci Rep. 2017;7:13021 pubmed publisher
Zhang F, Virshup D, Cheong J. Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis. Oncogene. 2018;37:363-376 pubmed publisher
Senturk S, Shirole N, Nowak D, Corbo V, Pal D, Vaughan A, et al. Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization. Nat Commun. 2017;8:14370 pubmed publisher
Huang Y, Chen N, Miao D. Radioprotective effects of pyrroloquinoline quinone on parotid glands in C57BL/6J mice. Exp Ther Med. 2016;12:3685-3693 pubmed publisher
Castellini L, Moon E, Razorenova O, Krieg A, von Eyben R, Giaccia A. KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage. Nucleic Acids Res. 2017;45:3674-3692 pubmed publisher
Wachter F, Morgan A, Godes M, Mourtada R, Bird G, Walensky L. Mechanistic validation of a clinical lead stapled peptide that reactivates p53 by dual HDM2 and HDMX targeting. Oncogene. 2017;36:2184-2190 pubmed publisher
Murray H, Maltby V, Smith D, Bowden N. Nucleotide excision repair deficiency in melanoma in response to UVA. Exp Hematol Oncol. 2015;5:6 pubmed publisher
Pages M, Lacroix L, Tauziède Espariat A, Castel D, Daudigeos Dubus E, Ridola V, et al. Papillary glioneuronal tumors: histological and molecular characteristics and diagnostic value of SLC44A1-PRKCA fusion. Acta Neuropathol Commun. 2015;3:85 pubmed publisher
Salas E, Roy S, Marsh T, Rubin B, Debnath J. Oxidative pentose phosphate pathway inhibition is a key determinant of antimalarial induced cancer cell death. Oncogene. 2016;35:2913-22 pubmed publisher
O Loghlen A, Brookes S, Martin N, Rapisarda V, Peters G, Gil J. CBX7 and miR-9 are part of an autoregulatory loop controlling p16(INK) (4a). Aging Cell. 2015;14:1113-21 pubmed publisher
Mondesert O, Frongia C, Clayton O, Boizeau M, Lobjois V, Ducommun B. Monitoring the Activation of the DNA Damage Response Pathway in a 3D Spheroid Model. PLoS ONE. 2015;10:e0134411 pubmed publisher
Sappino A, Buser R, Seguin Q, Fernet M, Lesne L, Gumy Pause F, et al. The CEACAM1 tumor suppressor is an ATM and p53-regulated gene required for the induction of cellular senescence by DNA damage. Oncogenesis. 2012;1:e7 pubmed publisher
Kopp F, Oak P, Wagner E, Roidl A. miR-200c sensitizes breast cancer cells to doxorubicin treatment by decreasing TrkB and Bmi1 expression. PLoS ONE. 2012;7:e50469 pubmed publisher
Vilotti S, Codrich M, Dal Ferro M, Pinto M, Ferrer I, Collavin L, et al. Parkinson's disease DJ-1 L166P alters rRNA biogenesis by exclusion of TTRAP from the nucleolus and sequestration into cytoplasmic aggregates via TRAF6. PLoS ONE. 2012;7:e35051 pubmed publisher
Korfali N, Srsen V, Waterfall M, Batrakou D, Pekovic V, Hutchison C, et al. A flow cytometry-based screen of nuclear envelope transmembrane proteins identifies NET4/Tmem53 as involved in stress-dependent cell cycle withdrawal. PLoS ONE. 2011;6:e18762 pubmed publisher
product information
Product Type :
Antibody
Product Name :
p53 Monoclonal Antibody (DO-1)
Catalog # :
AHO0152
Quantity :
500 µL
Price :
US 450.00
Clonality :
Monoclonal
Purity :
protein A
Host :
Mouse
Reactivity :
Human, Rhesus Monkey
Applications :
ChIP Assay: 1-3 µg x 10^6 cells, Immunocytochemistry: Assay-Dependent, Immunohistochemistry (Paraffin): Assay-Dependent, Immunoprecipitation: Assay-Dependent, Western Blot: Assay-Dependent
Species :
Human, Rhesus Monkey
Clone :
DO-1
Isotype :
IgG2a
Storage :
-20°C
Description :
The tumor suppressor protein, p53, is a sequence specific transcription factor that is activated by cellular stress. p53 mediates cell cycle arrest or apoptosis in response to DNA damage or starvation for pyrimidine nucleotides. p53 is up-regulated in response to stress signals and stimulated to activate transcription of specific genes, resulting in expression of p21waf1 and other proteins involved in G1 or G2/M arrest. The structure of p53 comprises an N-terminal transactivation domain, a central DNA-binding domain, an oligomerisation domain, and a C-terminal regulatory domain. There are various phosphorylation sites on p53, of which the phosphorylation at Ser15 is important for p53 activation and stabilization. p53 has been characterized to play a role in blocking the proliferative action of damaged cells and act as an anticancer agent. Phosphorylation of Ser392 in p53 has been shown to associate with the formation of human tumors. In addition, p53 has also been linked to the effects of aging and oxidative stress and an increase in p53 has been linked to deficits in LTP (Long Term Potentiation) in learning and memory. p53 is found in very low levels in normal cells, however, in a variety of transformed cell lines, it is expressed in high amounts, and believed to contribute to transformation and malignancy. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and cause the loss of tumor suppressor activity. Alterations of the TP53 gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families such as Li-Fraumeni syndrome.
Immunogen :
Recombinant human wild type p53 protein expressed in E. coli.
Format :
Liquid
Applications w/Dilutions :
ChIP Assay: 1-3 µg x 10^6 cells, Immunocytochemistry: Assay-Dependent, Immunohistochemistry (Paraffin): Assay-Dependent, Immunoprecipitation: Assay-Dependent, Western Blot: Assay-Dependent
Aliases :
Antigen NY-CO-13; bbl; BCC7; bfy; bhy; cellular tumor antigen p53; Cys 51 Stop; EGK_08142; FLJ92943; HGNC11998; I79_002739; LFS1; Li-Fraumeni syndrome; mutant p53; mutant tumor protein 53; OTTMUSP00000006194; p44; p53; p53 cellular tumor antigen; p53 protein; p53 tumor suppressor; p53 tumor suppressor phosphoprotein; phosphoprotein p53; Tp53; tp53.L; transformation related protein 53; transformation-related protein 53; Trp248; Trp53; tumor protein 53; tumor protein p53; tumor protein p53 (Li-Fraumeni syndrome); tumor protein p53 L homeolog; tumor suppressor p53; tumor suppressor p53 phosphoprotein; tumor suppressor protein p53; tumor supressor p53; Tumour Protein p53; XELAEV_180196761mg; Xp53; Xrel3
more info or order :
Invitrogen product webpage
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com
800-678-5599
headquarters: USA